Caraway Therapeutics, Inc.

Caraway Therapeutics, Inc. is a biotechnology startup founded in 2018, headquartered in the United States. The company's slogan, "Precision Medicines for CNS and Rare Diseases," reflects its focus on developing targeted therapies for neurodegenerative and rare diseases. Caraway's unique approach leverages genetic data to develop proprietary small molecules that activate cellular clearance and recycling processes, thereby accelerating the removal of toxic materials and defective cellular components. Their research focuses on the link between lysosomal function and pathologies in various organ systems, including the central nervous system, heart, kidney, and muscle. This makes the company a leader in developing potentially disease-modifying compounds for conditions such as Parkinson’s disease, Amyotrophic Lateral Sclerosis, and lysosomal storage diseases. Caraway's last investment, a grant from the Michael J. Fox Foundation in November 2020, highlights the recognition and support the company has received in its pursuit of innovative therapeutics.